{"ticker": {"uuid": "3264af35-eb5a-4c64-8c7b-379213ed9bd9", "symbol": "DNA", "name": "Ginkgo Bioworks Holdings", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Ginkgo Bioworks (NYSE: DNA) CFO logs RSU vesting and tax sell-to-cover", "summary": "Ginkgo Bioworks (NYSE: DNA) CFO Steven P. Coen reported the vesting of 1,486 restricted stock units (RSUs) on July 16, 2026. Following this, he sold 752 shares of Class A Common Stock on July 17, 2026, at $7.903 per share. This sale was a non-discretionary \"sell-to-cover\" transac", "url": "https://www.stocktitan.net/sec-filings/DNA/form-4-ginkgo-bioworks-holdings-inc-insider-trading-activity-eb72db254124.html", "source_name": "Stock Titan", "published_at": "2026-07-20T21:09:32", "published_display": "20 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (NYSE: DNA) insider Steve Coen plans Class A stock sale", "summary": "Ginkgo Bioworks insider Steve Coen has filed a Form 144 notice to sell 752 Class A common shares through Fidelity Brokerage Services. These shares originated from restricted stock vesting as compensation. The filing also reports previous Class A stock sales by Coen on April 17, 2", "url": "https://www.stocktitan.net/sec-filings/DNA/144-ginkgo-bioworks-holdings-inc-sec-filing-20617e92868a.html", "source_name": "Stock Titan", "published_at": "2026-07-17T20:40:47", "published_display": "17 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ginkgo Bioworks Holdings' Stock Sinks To US$9.07, But Insiders Sold Even Lower", "summary": "Ginkgo Bioworks Holdings, Inc.'s stock value dropped 12% in the last week, bringing it to US$9.07 per share. Despite this, company insiders who sold US$220k worth of stock last year did so at an average price of US$10.99, which was higher than the current share price. The article", "url": "https://www.sahmcapital.com/news/content/ginkgo-bioworks-holdings-stock-sinks-to-us907-but-insiders-sold-even-lower-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T02:10:08", "published_display": "10 Jul 2026 02:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Ginkgo Bioworks Holdings, Inc. Class A Stocks", "summary": "This article lists various ETFs that hold Ginkgo Bioworks Holdings, Inc. Class A stocks, providing details such as market value, weight, issuer, expense ratio, AUM, and 3-year NAV total return for each fund. The funds span different investment focuses, including artificial intell", "url": "https://www.tradingview.com/symbols/BIVA-DNA/etfs/", "source_name": "TradingView", "published_at": "2026-07-05T00:39:41", "published_display": "05 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings, Inc. Class A Actuals & Estimates (NYSE:DNA)", "summary": "This article provides an overview of Ginkgo Bioworks Holdings, Inc. (DNA) stock performance, financial data, and analyst forecasts. It covers recent stock price movements, market capitalization, earnings per share, revenue, and EBITDA. The report also highlights future earnings r", "url": "https://www.tradingview.com/symbols/NYSE-DNA/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T02:39:24", "published_display": "26 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "9L40 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Ginkgo Bioworks Holdings, Inc. Class A (9L40) for 2027, based on analyst opinions. It outlines historical price movements, financial reporting details including earnings and revenue, and key company metrics like EBITDA and emp", "url": "https://www.tradingview.com/symbols/TRADEGATE-9L40/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T01:39:24", "published_display": "26 Jun 2026 01:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (DNA) That Institutions Follow", "summary": "This article analyzes Ginkgo Bioworks Holdings Inc. (NYSE: DNA) using AI-generated technical signals. It highlights a near-term strong sentiment potentially challenging persistent mid- and long-term weakness, noting an exceptional 84.7:1 risk-reward short setup. The analysis prov", "url": "https://news.stocktradersdaily.com/news_release/17/The_Technical_Signals_Behind_DNA_That_Institutions_Follow_062126122602_1782015962.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T00:26:00", "published_display": "21 Jun 2026 00:26", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (DNA) director Henry Christian O receives 25,000 RSU equity grant", "summary": "Ginkgo Bioworks Holdings, Inc. director Henry Christian O was granted 25,000 restricted stock units (RSUs), as reported in a Form 4 filing. These RSUs represent a contingent right to receive one share of Class A common stock each and will vest on the earlier of June 11, 2027, or ", "url": "https://www.stocktitan.net/sec-filings/DNA/form-4-ginkgo-bioworks-holdings-inc-insider-trading-activity-e9851ddf11b1.html", "source_name": "Stock Titan", "published_at": "2026-06-16T04:10:08", "published_display": "16 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Ross Fubini receives 25,000 RSUs at Ginkgo Bioworks (NYSE: DNA)", "summary": "Ginkgo Bioworks (NYSE: DNA) director Ross Fubini was granted 25,000 Restricted Stock Units (RSUs) on June 11, 2026, as reported in a recent SEC Form 4 filing. These RSUs, which have no cash exercise price, will vest on the earlier of June 11, 2027, or the day before the next annu", "url": "https://www.stocktitan.net/sec-filings/DNA/form-4-ginkgo-bioworks-holdings-inc-insider-trading-activity-8b1a2b36fb01.html", "source_name": "Stock Titan", "published_at": "2026-06-16T04:10:07", "published_display": "16 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Ginkgo Bioworks (NYSE: DNA) granted 25,000 RSUs", "summary": "Ginkgo Bioworks director Sri Kosuri was granted 25,000 restricted stock units (RSUs) on June 11, 2026, as equity compensation. These RSUs, which represent contingent rights to receive Class A common stock, will vest on the earlier of June 11, 2027, or the day before the next annu", "url": "https://www.stocktitan.net/sec-filings/DNA/form-4-ginkgo-bioworks-holdings-inc-insider-trading-activity-bd4977783a39.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:10:08", "published_display": "15 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (DNA) director Harry Sloan awarded 25,000 RSUs", "summary": "Ginkgo Bioworks director Harry Sloan was granted 25,000 restricted stock units (RSUs) on June 11, 2026. These RSUs, which represent a contingent right to receive one share of Class A common stock per RSU, will vest on the earlier of June 11, 2027, or the day before the next annua", "url": "https://www.stocktitan.net/sec-filings/DNA/form-4-ginkgo-bioworks-holdings-inc-insider-trading-activity-38cf9cd9d3ad.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:10:07", "published_display": "15 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Shareholders Back Board, Governance Structure", "summary": "Ginkgo Bioworks Holdings (DNA) shareholders affirmed the company's existing board, governance structure, and executive compensation at their 2026 annual meeting. The strong shareholder turnout and approval signal stability for investors. Despite weak financial performance noted b", "url": "https://www.theglobeandmail.com/investing/markets/stocks/DNA/pressreleases/2458538/ginkgo-bioworks-shareholders-back-board-governance-structure/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T18:39:35", "published_display": "14 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (NYSE: DNA) shareholders approve directors, Deloitte and executive pay", "summary": "Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) shareholders approved the election of all six director nominees, ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026, and gave advisory approval to the compensation of the company's named executiv", "url": "https://www.stocktitan.net/sec-filings/DNA/8-k-ginkgo-bioworks-holdings-inc-reports-material-event-5a7ca744b998.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:09:03", "published_display": "12 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Austin Che files Form 144 to sell Class A shares | DNA SEC Filing - Form 144", "summary": "Austin Che, an insider at Ginkgo Bioworks Holdings, Inc. (DNA), has filed a Form 144 indicating proposed sales of Class A shares. The filing details multiple sale notifications through Fidelity Brokerage Services LLC, including sales of 2,200 shares on March 11, 2026, for $13,882", "url": "https://www.stocktitan.net/sec-filings/DNA/144-ginkgo-bioworks-holdings-inc-sec-filing-8542c3392a92.html", "source_name": "Stock Titan", "published_at": "2026-06-11T15:09:31", "published_display": "11 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Ginkgo Bioworks Holdings Inc. Class A (DNA) Risk Zones", "summary": "This article analyzes Ginkgo Bioworks Holdings Inc. Class A (NYSE: DNA) using AI models, highlighting a mid-channel oscillation pattern and an exceptional 133.0:1 risk-reward setup. It outlines three distinct trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014tailor", "url": "https://news.stocktradersdaily.com/news_release/21/Precision_Trading_with_Ginkgo_Bioworks_Holdings_Inc._Class_A_DNA_Risk_Zones_060926111802_1781061482.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-09T23:18:00", "published_display": "09 Jun 2026 23:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Ginkgo Bioworks Holdings, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Significant Losses to Contact the Firm", "summary": "Kessler Topaz Meltzer & Check, LLP is reminding shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) about an upcoming deadline for a securities fraud class action lawsuit. Investors who suffered significant losses during the class period of May 11, 2021, to October 5, 2021", "url": "https://www.newsfilecorp.com/release/108216/Kessler-Topaz-Meltzer-Check-LLP-Reminds-Shareholders-of-Ginkgo-Bioworks-Holdings-Inc.-of-Deadline-in-Securities-Fraud-Class-Action-Lawsuit-and-Encourages-Investors-with-Significant-Losses-to-Contact-the-Firm?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-06-02T07:39:55", "published_display": "02 Jun 2026 07:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings (NYSE:DNA) - Stock Analysis", "summary": "This Simply Wall St analysis provides a comprehensive overview of Ginkgo Bioworks Holdings (NYSE:DNA), detailing its valuation, growth prospects, past performance, and financial health. The article highlights recent corporate announcements, earnings reports, and analyst revisions", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dna/ginkgo-bioworks-holdings", "source_name": "Simply Wall Street", "published_at": "2026-05-27T20:39:02", "published_display": "27 May 2026 20:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (NYSE: DNA) insider logs RSU vesting and small tax-related share sale", "summary": "Ginkgo Bioworks (NYSE: DNA) insider Steven P. Coen reported routine equity compensation activity including RSU vesting and a related tax-related share sale. Coen exercised awards for 743 shares of Class A Common Stock at $0.00 per share and subsequently sold 307 shares at $8.334 ", "url": "https://www.stocktitan.net/sec-filings/DNA/form-4-ginkgo-bioworks-holdings-inc-insider-trading-activity-349eae7ce224.html", "source_name": "Stock Titan", "published_at": "2026-05-26T20:39:24", "published_display": "26 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One\u2122: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ginkgo-datapoints-tangible-scientific-inductive-163300116.html", "source_name": "PR Newswire", "published_at": "2026-05-26T16:33:00+00:00", "published_display": "26 May 2026 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Steve Coen (DNA) files Form 144 to sell 307 Class A shares", "summary": "Steve Coen has filed a Form 144 to sell 307 Class A shares of Ginkgo Bioworks Holdings, Inc. (DNA), stemming from a Restricted Stock Vesting event on May 21, 2026. This filing also discloses previous dispositions by Coen, totaling 33,903 shares between March and April 2026. The t", "url": "https://www.stocktitan.net/sec-filings/DNA/144-ginkgo-bioworks-holdings-inc-sec-filing-98e8650690cb.html", "source_name": "Stock Titan", "published_at": "2026-05-22T19:40:32", "published_display": "22 May 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings Inc (DNA): What\u2019s the Future of Autonomous Lab?", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ginkgo-bioworks-holdings-inc-dna-123605198.html", "source_name": "Insider Monkey", "published_at": "2026-05-22T12:36:05+00:00", "published_display": "22 May 2026 12:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Global (DNA) reports 3,577,128 shares, removes retired reporting person", "summary": "Viking Global Investors and its affiliated entities have reported a shared beneficial ownership of 3,577,128 shares of Class A Common Stock in Ginkgo Bioworks Holdings, Inc. (DNA), representing 7.1% of the outstanding shares as of March 31, 2026. This Schedule 13G/A amendment als", "url": "https://www.stocktitan.net/sec-filings/DNA/schedule-13g-a-ginkgo-bioworks-holdings-inc-amended-passive-investmen-23bf2c034a40.html", "source_name": "Stock Titan", "published_at": "2026-05-15T21:40:28", "published_display": "15 May 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts", "summary": "Analysts have significantly revised down their revenue forecasts for Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) for 2026, anticipating a 19% decline in sales. This pessimistic outlook suggests previous estimates were overly optimistic and places the company's revenue contraction s", "url": "https://www.sahmcapital.com/news/content/newsflash-ginkgo-bioworks-holdings-inc-nysedna-analysts-have-been-trimming-their-revenue-forecasts-2026-05-13", "source_name": "Sahm", "published_at": "2026-05-14T02:39:07", "published_display": "14 May 2026 02:39", "sentiment": "negative", "sentiment_pct": 26, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Austin Che files Form 144 to sell Class A shares (NASDAQ: DNA)", "summary": "Austin Che has filed a Form 144 to report proposed sales of Class A shares of Ginkgo Bioworks Holdings, Inc. (DNA). The filing indicates an intent to sell 2,200 Class A shares linked to a Restricted Stock Vesting from October 20, 2022. It also discloses sales totaling 45,293 shar", "url": "https://www.stocktitan.net/sec-filings/DNA/144-ginkgo-bioworks-holdings-inc-sec-filing-c0a86eaf97d8.html", "source_name": "Stock Titan", "published_at": "2026-05-13T15:09:16", "published_display": "13 May 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales Forecasts", "summary": "", "url": "https://finance.yahoo.com/news/ginkgo-bioworks-holdings-inc-nyse-114120664.html", "source_name": "Simply Wall St.", "published_at": "2026-05-13T11:41:20+00:00", "published_display": "13 May 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks: Another Lost Year (NYSE:DNA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE5XOGdMWE5qUnliVnVrb3NJbUxfWHA5dlZuak5BVzdNMm9HSkRQeTVKZ3h2bm5IMEhGd1NjdWtGcTU0WUFTR2ZqUmhFRmJOY2Z1UFFRd0xRUUtlOTBMZ1VEQXZjQkZJM1VKa2FkU2VKMUFnVkdRZ0VpTlJtMXBudnc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Ginkgo Bioworks (DNA) Story Is Shifting After The Biosecurity Divestiture And Target Cut", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNTGhxelhJVHpxY1RkOVYtZ2QtSTc5XzJSbk0wUmpacEdfVjdQSVlkVkl0bjl3ckhudF9mUk1WT18yMmhraVRhUXE1YWtRSzllRmxESlpQRzFUWW9uMnB3NmlBM2d3YmNDc05aeXhDZmNSVUg2SmpQeVhROG84YTcyZnRZT2NJanl0ajRzNUI3bk5UQWxSRTJUYi1Dd2ZZZjlR?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ginkgo Bioworks Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/67cedc0b-c645-38b6-8467-d46225b383b6/ginkgo-bioworks-q1-earnings.html", "source_name": "MarketBeat", "published_at": "2026-05-10T03:05:44+00:00", "published_display": "10 May 2026 03:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings (DNA) TTM Net Loss Of US$312.8 Million Reinforces Bearish Narratives", "summary": "Ginkgo Bioworks Holdings (DNA) reported a TTM net loss of US$312.8 million for FY 2025, with revenue declining from US$227.0 million to US$170.2 million. The company's EPS loss narrowed, but it is expected to remain unprofitable for at least three more years. Despite ongoing loss", "url": "https://www.sahmcapital.com/news/content/ginkgo-bioworks-holdings-dna-ttm-net-loss-of-us3128-million-reinforces-bearish-narratives-2026-05-09", "source_name": "Sahm", "published_at": "2026-05-09T13:09:18", "published_display": "09 May 2026 13:09", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (DNA) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/f104c2b4-f816-3b2b-8607-74e0ad17e2ec/ginkgo-bioworks-%28dna%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-08T20:11:10+00:00", "published_display": "08 May 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (NYSE: DNA) posts Q1 2026 loss and exits Biosecurity unit", "summary": "Ginkgo Bioworks (NYSE: DNA) reported a Q1 2026 net loss of $82.6 million, with revenue from continuing operations at $19.5 million. The company completed the strategic divestiture of its Biosecurity unit in April 2026, transferring operations in exchange for an approximate 20% eq", "url": "https://www.stocktitan.net/sec-filings/DNA/10-q-ginkgo-bioworks-holdings-inc-quarterly-earnings-report-4a13d2a00922.html", "source_name": "Stock Titan", "published_at": "2026-05-08T01:39:50", "published_display": "08 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwJBVV95cUxOM0M5eU5CNFlGbmhZSmtzTHJPV2lWSEVvVWhNeXVla1hjRVUzdmk0Qm9iSENpZ1dxZGRQNnExWE1qNnNHVVhoN0diUkc5cFlhZS1VWVZIdkhxbFg0WS1WTzJzSWlLcXNhQ3hsNVlIQlJ1ZmVBV2x1bk9aT0RyZnhwVlJtRkR3Sk03ZkJVSGRGMUJDeUFRMG0tM2tSdlVZX3R2bjh5enFwd2NITGhrbVJ6T0ZmQkhYNVV4SFpPd0pHdm8wemxrM2NkOVFiNmhvWW1VaDlEM2VMNERxSF9BYzZTeXJkU0J5UzFfZmE4b0ZBai01M21nbVhjNVZVa3J6R05LRmhQSE5KUHdGMUlGcUJsa25aaGV1RGxtSkZV?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings To Watch: Ginkgo Bioworks Holdings Inc (DNA) Reports Q1 2026 Result", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/earnings-watch-ginkgo-bioworks-holdings-132921804.html", "source_name": "GuruFocus.com", "published_at": "2026-05-06T13:29:21+00:00", "published_display": "06 May 2026 13:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNA SEC Filings - Ginkgo Bioworks Holdings Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for investors to access Ginkgo Bioworks Holdings Inc. (NYSE: DNA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. Recent 8-K filings cover financial results, stock offe", "url": "https://www.stocktitan.net/sec-filings/DNA/page-7.html", "source_name": "Stock Titan", "published_at": "2026-05-04T11:39:59", "published_display": "04 May 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation", "summary": "Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) announced that it will host a presentation and Q&A session to review its business performance for the first quarter ended March 31, 2026. This session is scheduled for Thursday, May 7, 2026, at 4:30 p.m. ET. Presentation details and a we", "url": "https://www.morningstar.com/news/pr-newswire/20260430ne46844/ginkgo-bioworks-announces-date-of-first-quarter-2026-results-presentation", "source_name": "Morningstar", "published_at": "2026-04-30T12:01:00", "published_display": "30 Apr 2026 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Ginkgo Bioworks Holdings (NYSE:DNA) Spend Its Cash Wisely?", "summary": "Ginkgo Bioworks Holdings (NYSE:DNA) currently has a cash runway of about 2.4 years based on its US$423m cash reserves and US$179m annual cash burn. While the company reduced its cash burn by 53% last year, revenue also dipped by 25%. Raising more capital could lead to significant", "url": "https://www.sahmcapital.com/news/content/will-ginkgo-bioworks-holdings-nysedna-spend-its-cash-wisely-2026-04-30", "source_name": "Sahm", "published_at": "2026-04-30T09:10:44", "published_display": "30 Apr 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks will take investor questions after May 7 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNNUFOVTFsT3dKTmNOMFZEMFd4T0loU19GdFFmdHVrOW5ta0JYS2djSVpqRDhINDVwVDZ6cmFhdk81NTNKdEtBY09DY2xWZExJVGNpQkYtMy1ueGUySU9JTnhsZFh2SmEza3BVUThURm9fR3llUzhiemRMeVN2WXpaOFNtd21leGREOVFxLUVwR3h3OWtyNzZRM1lXMGZkRGY0V3V2c3pvQjk4OUs4STV3N1Zsc20?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (NYSE: DNA) sets 2026 virtual meeting, auditor and pay votes", "summary": "Ginkgo Bioworks will hold its virtual 2026 annual shareholder meeting on June 11, 2026, where shareholders will vote on the election of six directors, the ratification of Deloitte & Touche LLP as the independent auditor for 2026, and an advisory vote on executive compensation. Th", "url": "https://www.stocktitan.net/sec-filings/DNA/def-14a-ginkgo-bioworks-holdings-inc-definitive-proxy-statement-b6d5ef8d5425.html", "source_name": "Stock Titan", "published_at": "2026-04-29T20:39:14", "published_display": "29 Apr 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ginkgo Bioworks CFO Steven Coen sells $2,576 in shares By Investing.com", "summary": "Ginkgo Bioworks CFO Steven Coen sold 324 shares of the company's Class A Common Stock for approximately $2,576. This transaction was primarily to cover tax withholding obligations related to the vesting of restricted stock and not a discretionary trade. The sale occurred after Mr", "url": "https://za.investing.com/news/insider-trading-news/ginkgo-bioworks-cfo-steven-coen-sells-2576-in-shares-93CH-4221561", "source_name": "Investing.com South Africa", "published_at": "2026-04-20T23:24:00", "published_display": "20 Apr 2026 23:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks CFO Steven Coen sells $2,576 in shares", "summary": "Ginkgo Bioworks CFO Steven Coen sold 324 shares of Class A Common Stock for approximately $2,576 to cover tax withholding obligations. This transaction followed his acquisition of 743 shares through RSU vesting on April 16, 2026, bringing his direct holdings to 50,268 shares. The", "url": "https://m.investing.com/news/insider-trading-news/ginkgo-bioworks-cfo-steven-coen-sells-2576-in-shares-93CH-4624783?ampMode=1", "source_name": "Investing.com", "published_at": "2026-04-20T21:39:42", "published_display": "20 Apr 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Proposed Class A sale by DNA (NYSE: DNA) \u2014 Form 144 lists 40,893 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQREJaWElvcE1oRXhMVF8wdUlYcHAtOU9vZ09tOVU2S3JGVV9mMV9mS1UzVDVWSTc2Z1pNSnJkVG1sYXNpUFFfa2RaZXBVSFRUVU83Q1VFWEs1R1J2TjhWRHlPa3g1OHdzMm5pYzYweHNxZ0pSVF9yUkJSemtQOVFtMlZMRXFobnA0blNDV3E1TGQ5REIwTk9lZ1h5Y3FaVS1venFYUmdKYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jason Kelly to sell 109,767 Class A shares (NYSE: DNA) under Form 144", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQSjBIbXoyb0FKOTVlR3did01TaFZzOTdOaVQyb3UtWTJ3R0JhSm1VUTVnV01hX1ZfMHNKSi1xSjRybHQ5c2UwNUxuQUNRMjNzY3pyWllFRGhHNFpMcGZiMUFZajRMSEVxbVdLUGFJb2xIenpSMTZ4NFh1N2REMlk0blNTamFZVWg2dmtDbWtlRkpDcXNHLUFjVkt1UVVHNUF4UjgxdF8wdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Ginkgo Bioworks (DNA) Valuation As It Pivots To Robotics Labs And Biosecurity Divestiture", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-01T08:00:00+00:00", "published_display": "01 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Ginkgo Bioworks (DNA) Valuation After Earnings Update And Invaio Collaboration", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxObTJGalBXUGdMYkszUUZpeE1RRHZrMzRBZmktNDZQNmlldWRQZjh2aER4dV9kejNiSVNCN1FmZHFwZHJLeVJGSnROT3dseTRfb2FkQXdBSnFfQ0pSdU5Pd2JlWjd1UTMyLWg2LVZxTFJncTlkWmFseGZtZVRtaG0za2pPaUpaYkU?oc=5", "source_name": "Market source", "published_at": "2026-03-01T08:00:00+00:00", "published_display": "01 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgJBVV95cUxNdms5RUEzVXpKdm5NaXQ3eHY4SXRyVmZVenZ0V0Q0bjZEZzZidmhmUVVLRjFWOElPQkUwUjVGSHhGNTJ0S0JteWNtTXhCTDdkNkhhME9VcmVldkFiMEVyTFFPZFlMOEZuNVdVQnFYRmRVOFduaWgyT3hYcWlNRUtHRmlnRzJSN1QyQjFSZENYMElHcFl4S1pndFhPQmhKVFo0MlpKazVnbk5WRHN1Rl9xeXB6UDVZTVdEeERIQklTUTFVLVVOekYwWXV6Z1ZwOEk3MEk1eUg2dngtXzBPYzgtYWM0cXBpX2RrMHhfYl9kTUUxdm5ZUmlvQkZvMERzVE5uelpEXzBpTUlWbS1xTGpSeXRrbVZNV19zdUFCVTA2Y0pWdzZnaS1xVXlnR0tzZmptOUozWno3Sll4ZmxGYkdDWHVfX0tLdFRYSGdIMWxB?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOclJCZUlkemN1MXAwdGVVZ3FiRmxDVEZUYUxHWktMMkhETVZ1SUZBR0lLQ3RnRXE2WmMtUHUzZlJWTjdaZDl4ZU4waFdwbVFPTERVRElnMjdUZ2lONjBWeTlCdGx4VzhQZTFvcUdfaW1mUU1aTmtVOW1LQ0w5N1lWN2hCZ3I?oc=5", "source_name": "Market source", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOQk9UU2xCR0hBaktaT1FzOFU2S1JsWnZEUngtVV9oRzJyS0lQYXBoaDg1NEQ1b3NGNUhhU3UyZXNqMzFYb21VNGFnWVl1YV9VTExxQTVUQnJBRDdIZlZxZWpoMkhiTjRCR2RCSFpaaHdzOGZMdTFNNUljYXJWVm0xMm1iTGJ3UlNjTFJ6WmhOMHhmOENKMVJsczJCM3RSN0pUWFplVml1TUF1VV9VSzJmUDdzUHFwU1hQaG8zZEZkQ19OdEFYdDZYOWpUQ1NsZTVzdjBuM2lMWDFfUFZNeVZnRVl2c0RHUFoybUJOZDVaamdvQnc?oc=5", "source_name": "SynBioBeta", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) institutional owners may be pleased with recent gains after 29% loss over the past year", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-08T08:00:00+00:00", "published_display": "08 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Ginkgo Bioworks Holdings, Inc. (DNA) Dipped More Than Broader Market Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxNdXJVb0F6ZWt3dWxTRlhlMnl5MjN2M0NCWDY4SHBuQTlja0Y1N21LNnBtTVUzMm1SSnlHc0V1VVJBWGNXaTNFd0g5SHMxRDZ3WUpucnN6YVVGS2Y3WkFzSGN3YTFfRWJsX1FVWHpDS1NtZ3hxSjZpemxKMkJGUjRVMll0UGw?oc=5", "source_name": "Market source", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price Today: $8.29", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE9USzZmVUtTdzFEWHdib2szTDF3bFhhTXJqZk55cGFjbFktOGJGaWRWZmJKamJ2NkRYVHpHeTh4bFN3ekZONklFMkNIWlhOWUNTSlBWaGNn?oc=5", "source_name": "Gotrade", "published_at": "2026-01-09T20:48:22+00:00", "published_display": "09 Jan 2026 20:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Investors Shouldn't Be Surprised By Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 39% Share Price Plunge", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-17T08:00:00+00:00", "published_display": "17 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Ginkgo Bioworks (NYSE: DNA) CFO logs RSU vesting and tax sell-to-cover", "summary": "Ginkgo Bioworks (NYSE: DNA) CFO Steven P. Coen reported the vesting of 1,486 restricted stock units (RSUs) on July 16, 2026. Following this, he sold 752 shares of Class A Common Stock on July 17, 2026, at $7.903 per share. This sale was a non-discretionary \"sell-to-cover\" transac", "url": "https://www.stocktitan.net/sec-filings/DNA/form-4-ginkgo-bioworks-holdings-inc-insider-trading-activity-eb72db254124.html", "source_name": "Stock Titan", "published_at": "2026-07-20T21:09:32", "published_display": "20 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (NYSE: DNA) insider Steve Coen plans Class A stock sale", "summary": "Ginkgo Bioworks insider Steve Coen has filed a Form 144 notice to sell 752 Class A common shares through Fidelity Brokerage Services. These shares originated from restricted stock vesting as compensation. The filing also reports previous Class A stock sales by Coen on April 17, 2", "url": "https://www.stocktitan.net/sec-filings/DNA/144-ginkgo-bioworks-holdings-inc-sec-filing-20617e92868a.html", "source_name": "Stock Titan", "published_at": "2026-07-17T20:40:47", "published_display": "17 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings' Stock Sinks To US$9.07, But Insiders Sold Even Lower", "summary": "Ginkgo Bioworks Holdings, Inc.'s stock value dropped 12% in the last week, bringing it to US$9.07 per share. Despite this, company insiders who sold US$220k worth of stock last year did so at an average price of US$10.99, which was higher than the current share price. The article", "url": "https://www.sahmcapital.com/news/content/ginkgo-bioworks-holdings-stock-sinks-to-us907-but-insiders-sold-even-lower-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T02:10:08", "published_display": "10 Jul 2026 02:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Ginkgo Bioworks Holdings, Inc. Class A Stocks", "summary": "This article lists various ETFs that hold Ginkgo Bioworks Holdings, Inc. Class A stocks, providing details such as market value, weight, issuer, expense ratio, AUM, and 3-year NAV total return for each fund. The funds span different investment focuses, including artificial intell", "url": "https://www.tradingview.com/symbols/BIVA-DNA/etfs/", "source_name": "TradingView", "published_at": "2026-07-05T00:39:41", "published_display": "05 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings, Inc. Class A Actuals & Estimates (NYSE:DNA)", "summary": "This article provides an overview of Ginkgo Bioworks Holdings, Inc. (DNA) stock performance, financial data, and analyst forecasts. It covers recent stock price movements, market capitalization, earnings per share, revenue, and EBITDA. The report also highlights future earnings r", "url": "https://www.tradingview.com/symbols/NYSE-DNA/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T02:39:24", "published_display": "26 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "9L40 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Ginkgo Bioworks Holdings, Inc. Class A (9L40) for 2027, based on analyst opinions. It outlines historical price movements, financial reporting details including earnings and revenue, and key company metrics like EBITDA and emp", "url": "https://www.tradingview.com/symbols/TRADEGATE-9L40/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T01:39:24", "published_display": "26 Jun 2026 01:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (DNA) That Institutions Follow", "summary": "This article analyzes Ginkgo Bioworks Holdings Inc. (NYSE: DNA) using AI-generated technical signals. It highlights a near-term strong sentiment potentially challenging persistent mid- and long-term weakness, noting an exceptional 84.7:1 risk-reward short setup. The analysis prov", "url": "https://news.stocktradersdaily.com/news_release/17/The_Technical_Signals_Behind_DNA_That_Institutions_Follow_062126122602_1782015962.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T00:26:00", "published_display": "21 Jun 2026 00:26", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (DNA) director Henry Christian O receives 25,000 RSU equity grant", "summary": "Ginkgo Bioworks Holdings, Inc. director Henry Christian O was granted 25,000 restricted stock units (RSUs), as reported in a Form 4 filing. These RSUs represent a contingent right to receive one share of Class A common stock each and will vest on the earlier of June 11, 2027, or ", "url": "https://www.stocktitan.net/sec-filings/DNA/form-4-ginkgo-bioworks-holdings-inc-insider-trading-activity-e9851ddf11b1.html", "source_name": "Stock Titan", "published_at": "2026-06-16T04:10:08", "published_display": "16 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Ross Fubini receives 25,000 RSUs at Ginkgo Bioworks (NYSE: DNA)", "summary": "Ginkgo Bioworks (NYSE: DNA) director Ross Fubini was granted 25,000 Restricted Stock Units (RSUs) on June 11, 2026, as reported in a recent SEC Form 4 filing. These RSUs, which have no cash exercise price, will vest on the earlier of June 11, 2027, or the day before the next annu", "url": "https://www.stocktitan.net/sec-filings/DNA/form-4-ginkgo-bioworks-holdings-inc-insider-trading-activity-8b1a2b36fb01.html", "source_name": "Stock Titan", "published_at": "2026-06-16T04:10:07", "published_display": "16 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Ginkgo Bioworks (NYSE: DNA) granted 25,000 RSUs", "summary": "Ginkgo Bioworks director Sri Kosuri was granted 25,000 restricted stock units (RSUs) on June 11, 2026, as equity compensation. These RSUs, which represent contingent rights to receive Class A common stock, will vest on the earlier of June 11, 2027, or the day before the next annu", "url": "https://www.stocktitan.net/sec-filings/DNA/form-4-ginkgo-bioworks-holdings-inc-insider-trading-activity-bd4977783a39.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:10:08", "published_display": "15 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (DNA) director Harry Sloan awarded 25,000 RSUs", "summary": "Ginkgo Bioworks director Harry Sloan was granted 25,000 restricted stock units (RSUs) on June 11, 2026. These RSUs, which represent a contingent right to receive one share of Class A common stock per RSU, will vest on the earlier of June 11, 2027, or the day before the next annua", "url": "https://www.stocktitan.net/sec-filings/DNA/form-4-ginkgo-bioworks-holdings-inc-insider-trading-activity-38cf9cd9d3ad.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:10:07", "published_display": "15 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Shareholders Back Board, Governance Structure", "summary": "Ginkgo Bioworks Holdings (DNA) shareholders affirmed the company's existing board, governance structure, and executive compensation at their 2026 annual meeting. The strong shareholder turnout and approval signal stability for investors. Despite weak financial performance noted b", "url": "https://www.theglobeandmail.com/investing/markets/stocks/DNA/pressreleases/2458538/ginkgo-bioworks-shareholders-back-board-governance-structure/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T18:39:35", "published_display": "14 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (NYSE: DNA) shareholders approve directors, Deloitte and executive pay", "summary": "Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) shareholders approved the election of all six director nominees, ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026, and gave advisory approval to the compensation of the company's named executiv", "url": "https://www.stocktitan.net/sec-filings/DNA/8-k-ginkgo-bioworks-holdings-inc-reports-material-event-5a7ca744b998.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:09:03", "published_display": "12 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Austin Che files Form 144 to sell Class A shares | DNA SEC Filing - Form 144", "summary": "Austin Che, an insider at Ginkgo Bioworks Holdings, Inc. (DNA), has filed a Form 144 indicating proposed sales of Class A shares. The filing details multiple sale notifications through Fidelity Brokerage Services LLC, including sales of 2,200 shares on March 11, 2026, for $13,882", "url": "https://www.stocktitan.net/sec-filings/DNA/144-ginkgo-bioworks-holdings-inc-sec-filing-8542c3392a92.html", "source_name": "Stock Titan", "published_at": "2026-06-11T15:09:31", "published_display": "11 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Ginkgo Bioworks Holdings Inc. Class A (DNA) Risk Zones", "summary": "This article analyzes Ginkgo Bioworks Holdings Inc. Class A (NYSE: DNA) using AI models, highlighting a mid-channel oscillation pattern and an exceptional 133.0:1 risk-reward setup. It outlines three distinct trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014tailor", "url": "https://news.stocktradersdaily.com/news_release/21/Precision_Trading_with_Ginkgo_Bioworks_Holdings_Inc._Class_A_DNA_Risk_Zones_060926111802_1781061482.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-09T23:18:00", "published_display": "09 Jun 2026 23:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Ginkgo Bioworks Holdings, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Significant Losses to Contact the Firm", "summary": "Kessler Topaz Meltzer & Check, LLP is reminding shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) about an upcoming deadline for a securities fraud class action lawsuit. Investors who suffered significant losses during the class period of May 11, 2021, to October 5, 2021", "url": "https://www.newsfilecorp.com/release/108216/Kessler-Topaz-Meltzer-Check-LLP-Reminds-Shareholders-of-Ginkgo-Bioworks-Holdings-Inc.-of-Deadline-in-Securities-Fraud-Class-Action-Lawsuit-and-Encourages-Investors-with-Significant-Losses-to-Contact-the-Firm?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-06-02T07:39:55", "published_display": "02 Jun 2026 07:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings (NYSE:DNA) - Stock Analysis", "summary": "This Simply Wall St analysis provides a comprehensive overview of Ginkgo Bioworks Holdings (NYSE:DNA), detailing its valuation, growth prospects, past performance, and financial health. The article highlights recent corporate announcements, earnings reports, and analyst revisions", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dna/ginkgo-bioworks-holdings", "source_name": "Simply Wall Street", "published_at": "2026-05-27T20:39:02", "published_display": "27 May 2026 20:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (NYSE: DNA) insider logs RSU vesting and small tax-related share sale", "summary": "Ginkgo Bioworks (NYSE: DNA) insider Steven P. Coen reported routine equity compensation activity including RSU vesting and a related tax-related share sale. Coen exercised awards for 743 shares of Class A Common Stock at $0.00 per share and subsequently sold 307 shares at $8.334 ", "url": "https://www.stocktitan.net/sec-filings/DNA/form-4-ginkgo-bioworks-holdings-inc-insider-trading-activity-349eae7ce224.html", "source_name": "Stock Titan", "published_at": "2026-05-26T20:39:24", "published_display": "26 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One\u2122: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ginkgo-datapoints-tangible-scientific-inductive-163300116.html", "source_name": "PR Newswire", "published_at": "2026-05-26T16:33:00+00:00", "published_display": "26 May 2026 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Steve Coen (DNA) files Form 144 to sell 307 Class A shares", "summary": "Steve Coen has filed a Form 144 to sell 307 Class A shares of Ginkgo Bioworks Holdings, Inc. (DNA), stemming from a Restricted Stock Vesting event on May 21, 2026. This filing also discloses previous dispositions by Coen, totaling 33,903 shares between March and April 2026. The t", "url": "https://www.stocktitan.net/sec-filings/DNA/144-ginkgo-bioworks-holdings-inc-sec-filing-98e8650690cb.html", "source_name": "Stock Titan", "published_at": "2026-05-22T19:40:32", "published_display": "22 May 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings Inc (DNA): What\u2019s the Future of Autonomous Lab?", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ginkgo-bioworks-holdings-inc-dna-123605198.html", "source_name": "Insider Monkey", "published_at": "2026-05-22T12:36:05+00:00", "published_display": "22 May 2026 12:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Global (DNA) reports 3,577,128 shares, removes retired reporting person", "summary": "Viking Global Investors and its affiliated entities have reported a shared beneficial ownership of 3,577,128 shares of Class A Common Stock in Ginkgo Bioworks Holdings, Inc. (DNA), representing 7.1% of the outstanding shares as of March 31, 2026. This Schedule 13G/A amendment als", "url": "https://www.stocktitan.net/sec-filings/DNA/schedule-13g-a-ginkgo-bioworks-holdings-inc-amended-passive-investmen-23bf2c034a40.html", "source_name": "Stock Titan", "published_at": "2026-05-15T21:40:28", "published_display": "15 May 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts", "summary": "Analysts have significantly revised down their revenue forecasts for Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) for 2026, anticipating a 19% decline in sales. This pessimistic outlook suggests previous estimates were overly optimistic and places the company's revenue contraction s", "url": "https://www.sahmcapital.com/news/content/newsflash-ginkgo-bioworks-holdings-inc-nysedna-analysts-have-been-trimming-their-revenue-forecasts-2026-05-13", "source_name": "Sahm", "published_at": "2026-05-14T02:39:07", "published_display": "14 May 2026 02:39", "sentiment": "negative", "sentiment_pct": 26, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Austin Che files Form 144 to sell Class A shares (NASDAQ: DNA)", "summary": "Austin Che has filed a Form 144 to report proposed sales of Class A shares of Ginkgo Bioworks Holdings, Inc. (DNA). The filing indicates an intent to sell 2,200 Class A shares linked to a Restricted Stock Vesting from October 20, 2022. It also discloses sales totaling 45,293 shar", "url": "https://www.stocktitan.net/sec-filings/DNA/144-ginkgo-bioworks-holdings-inc-sec-filing-c0a86eaf97d8.html", "source_name": "Stock Titan", "published_at": "2026-05-13T15:09:16", "published_display": "13 May 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales Forecasts", "summary": "", "url": "https://finance.yahoo.com/news/ginkgo-bioworks-holdings-inc-nyse-114120664.html", "source_name": "Simply Wall St.", "published_at": "2026-05-13T11:41:20+00:00", "published_display": "13 May 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks: Another Lost Year (NYSE:DNA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE5XOGdMWE5qUnliVnVrb3NJbUxfWHA5dlZuak5BVzdNMm9HSkRQeTVKZ3h2bm5IMEhGd1NjdWtGcTU0WUFTR2ZqUmhFRmJOY2Z1UFFRd0xRUUtlOTBMZ1VEQXZjQkZJM1VKa2FkU2VKMUFnVkdRZ0VpTlJtMXBudnc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Ginkgo Bioworks (DNA) Story Is Shifting After The Biosecurity Divestiture And Target Cut", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNTGhxelhJVHpxY1RkOVYtZ2QtSTc5XzJSbk0wUmpacEdfVjdQSVlkVkl0bjl3ckhudF9mUk1WT18yMmhraVRhUXE1YWtRSzllRmxESlpQRzFUWW9uMnB3NmlBM2d3YmNDc05aeXhDZmNSVUg2SmpQeVhROG84YTcyZnRZT2NJanl0ajRzNUI3bk5UQWxSRTJUYi1Dd2ZZZjlR?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/67cedc0b-c645-38b6-8467-d46225b383b6/ginkgo-bioworks-q1-earnings.html", "source_name": "MarketBeat", "published_at": "2026-05-10T03:05:44+00:00", "published_display": "10 May 2026 03:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings (DNA) TTM Net Loss Of US$312.8 Million Reinforces Bearish Narratives", "summary": "Ginkgo Bioworks Holdings (DNA) reported a TTM net loss of US$312.8 million for FY 2025, with revenue declining from US$227.0 million to US$170.2 million. The company's EPS loss narrowed, but it is expected to remain unprofitable for at least three more years. Despite ongoing loss", "url": "https://www.sahmcapital.com/news/content/ginkgo-bioworks-holdings-dna-ttm-net-loss-of-us3128-million-reinforces-bearish-narratives-2026-05-09", "source_name": "Sahm", "published_at": "2026-05-09T13:09:18", "published_display": "09 May 2026 13:09", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (DNA) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/f104c2b4-f816-3b2b-8607-74e0ad17e2ec/ginkgo-bioworks-%28dna%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-08T20:11:10+00:00", "published_display": "08 May 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (NYSE: DNA) posts Q1 2026 loss and exits Biosecurity unit", "summary": "Ginkgo Bioworks (NYSE: DNA) reported a Q1 2026 net loss of $82.6 million, with revenue from continuing operations at $19.5 million. The company completed the strategic divestiture of its Biosecurity unit in April 2026, transferring operations in exchange for an approximate 20% eq", "url": "https://www.stocktitan.net/sec-filings/DNA/10-q-ginkgo-bioworks-holdings-inc-quarterly-earnings-report-4a13d2a00922.html", "source_name": "Stock Titan", "published_at": "2026-05-08T01:39:50", "published_display": "08 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwJBVV95cUxOM0M5eU5CNFlGbmhZSmtzTHJPV2lWSEVvVWhNeXVla1hjRVUzdmk0Qm9iSENpZ1dxZGRQNnExWE1qNnNHVVhoN0diUkc5cFlhZS1VWVZIdkhxbFg0WS1WTzJzSWlLcXNhQ3hsNVlIQlJ1ZmVBV2x1bk9aT0RyZnhwVlJtRkR3Sk03ZkJVSGRGMUJDeUFRMG0tM2tSdlVZX3R2bjh5enFwd2NITGhrbVJ6T0ZmQkhYNVV4SFpPd0pHdm8wemxrM2NkOVFiNmhvWW1VaDlEM2VMNERxSF9BYzZTeXJkU0J5UzFfZmE4b0ZBai01M21nbVhjNVZVa3J6R05LRmhQSE5KUHdGMUlGcUJsa25aaGV1RGxtSkZV?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings To Watch: Ginkgo Bioworks Holdings Inc (DNA) Reports Q1 2026 Result", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/earnings-watch-ginkgo-bioworks-holdings-132921804.html", "source_name": "GuruFocus.com", "published_at": "2026-05-06T13:29:21+00:00", "published_display": "06 May 2026 13:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNA SEC Filings - Ginkgo Bioworks Holdings Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for investors to access Ginkgo Bioworks Holdings Inc. (NYSE: DNA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. Recent 8-K filings cover financial results, stock offe", "url": "https://www.stocktitan.net/sec-filings/DNA/page-7.html", "source_name": "Stock Titan", "published_at": "2026-05-04T11:39:59", "published_display": "04 May 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation", "summary": "Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) announced that it will host a presentation and Q&A session to review its business performance for the first quarter ended March 31, 2026. This session is scheduled for Thursday, May 7, 2026, at 4:30 p.m. ET. Presentation details and a we", "url": "https://www.morningstar.com/news/pr-newswire/20260430ne46844/ginkgo-bioworks-announces-date-of-first-quarter-2026-results-presentation", "source_name": "Morningstar", "published_at": "2026-04-30T12:01:00", "published_display": "30 Apr 2026 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Ginkgo Bioworks Holdings (NYSE:DNA) Spend Its Cash Wisely?", "summary": "Ginkgo Bioworks Holdings (NYSE:DNA) currently has a cash runway of about 2.4 years based on its US$423m cash reserves and US$179m annual cash burn. While the company reduced its cash burn by 53% last year, revenue also dipped by 25%. Raising more capital could lead to significant", "url": "https://www.sahmcapital.com/news/content/will-ginkgo-bioworks-holdings-nysedna-spend-its-cash-wisely-2026-04-30", "source_name": "Sahm", "published_at": "2026-04-30T09:10:44", "published_display": "30 Apr 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks will take investor questions after May 7 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNNUFOVTFsT3dKTmNOMFZEMFd4T0loU19GdFFmdHVrOW5ta0JYS2djSVpqRDhINDVwVDZ6cmFhdk81NTNKdEtBY09DY2xWZExJVGNpQkYtMy1ueGUySU9JTnhsZFh2SmEza3BVUThURm9fR3llUzhiemRMeVN2WXpaOFNtd21leGREOVFxLUVwR3h3OWtyNzZRM1lXMGZkRGY0V3V2c3pvQjk4OUs4STV3N1Zsc20?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks (NYSE: DNA) sets 2026 virtual meeting, auditor and pay votes", "summary": "Ginkgo Bioworks will hold its virtual 2026 annual shareholder meeting on June 11, 2026, where shareholders will vote on the election of six directors, the ratification of Deloitte & Touche LLP as the independent auditor for 2026, and an advisory vote on executive compensation. Th", "url": "https://www.stocktitan.net/sec-filings/DNA/def-14a-ginkgo-bioworks-holdings-inc-definitive-proxy-statement-b6d5ef8d5425.html", "source_name": "Stock Titan", "published_at": "2026-04-29T20:39:14", "published_display": "29 Apr 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks CFO Steven Coen sells $2,576 in shares By Investing.com", "summary": "Ginkgo Bioworks CFO Steven Coen sold 324 shares of the company's Class A Common Stock for approximately $2,576. This transaction was primarily to cover tax withholding obligations related to the vesting of restricted stock and not a discretionary trade. The sale occurred after Mr", "url": "https://za.investing.com/news/insider-trading-news/ginkgo-bioworks-cfo-steven-coen-sells-2576-in-shares-93CH-4221561", "source_name": "Investing.com South Africa", "published_at": "2026-04-20T23:24:00", "published_display": "20 Apr 2026 23:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks CFO Steven Coen sells $2,576 in shares", "summary": "Ginkgo Bioworks CFO Steven Coen sold 324 shares of Class A Common Stock for approximately $2,576 to cover tax withholding obligations. This transaction followed his acquisition of 743 shares through RSU vesting on April 16, 2026, bringing his direct holdings to 50,268 shares. The", "url": "https://m.investing.com/news/insider-trading-news/ginkgo-bioworks-cfo-steven-coen-sells-2576-in-shares-93CH-4624783?ampMode=1", "source_name": "Investing.com", "published_at": "2026-04-20T21:39:42", "published_display": "20 Apr 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Proposed Class A sale by DNA (NYSE: DNA) \u2014 Form 144 lists 40,893 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQREJaWElvcE1oRXhMVF8wdUlYcHAtOU9vZ09tOVU2S3JGVV9mMV9mS1UzVDVWSTc2Z1pNSnJkVG1sYXNpUFFfa2RaZXBVSFRUVU83Q1VFWEs1R1J2TjhWRHlPa3g1OHdzMm5pYzYweHNxZ0pSVF9yUkJSemtQOVFtMlZMRXFobnA0blNDV3E1TGQ5REIwTk9lZ1h5Y3FaVS1venFYUmdKYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jason Kelly to sell 109,767 Class A shares (NYSE: DNA) under Form 144", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQSjBIbXoyb0FKOTVlR3did01TaFZzOTdOaVQyb3UtWTJ3R0JhSm1VUTVnV01hX1ZfMHNKSi1xSjRybHQ5c2UwNUxuQUNRMjNzY3pyWllFRGhHNFpMcGZiMUFZajRMSEVxbVdLUGFJb2xIenpSMTZ4NFh1N2REMlk0blNTamFZVWg2dmtDbWtlRkpDcXNHLUFjVkt1UVVHNUF4UjgxdF8wdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Ginkgo Bioworks (DNA) Valuation As It Pivots To Robotics Labs And Biosecurity Divestiture", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-01T08:00:00+00:00", "published_display": "01 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Ginkgo Bioworks (DNA) Valuation After Earnings Update And Invaio Collaboration", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxObTJGalBXUGdMYkszUUZpeE1RRHZrMzRBZmktNDZQNmlldWRQZjh2aER4dV9kejNiSVNCN1FmZHFwZHJLeVJGSnROT3dseTRfb2FkQXdBSnFfQ0pSdU5Pd2JlWjd1UTMyLWg2LVZxTFJncTlkWmFseGZtZVRtaG0za2pPaUpaYkU?oc=5", "source_name": "Market source", "published_at": "2026-03-01T08:00:00+00:00", "published_display": "01 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgJBVV95cUxNdms5RUEzVXpKdm5NaXQ3eHY4SXRyVmZVenZ0V0Q0bjZEZzZidmhmUVVLRjFWOElPQkUwUjVGSHhGNTJ0S0JteWNtTXhCTDdkNkhhME9VcmVldkFiMEVyTFFPZFlMOEZuNVdVQnFYRmRVOFduaWgyT3hYcWlNRUtHRmlnRzJSN1QyQjFSZENYMElHcFl4S1pndFhPQmhKVFo0MlpKazVnbk5WRHN1Rl9xeXB6UDVZTVdEeERIQklTUTFVLVVOekYwWXV6Z1ZwOEk3MEk1eUg2dngtXzBPYzgtYWM0cXBpX2RrMHhfYl9kTUUxdm5ZUmlvQkZvMERzVE5uelpEXzBpTUlWbS1xTGpSeXRrbVZNV19zdUFCVTA2Y0pWdzZnaS1xVXlnR0tzZmptOUozWno3Sll4ZmxGYkdDWHVfX0tLdFRYSGdIMWxB?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOclJCZUlkemN1MXAwdGVVZ3FiRmxDVEZUYUxHWktMMkhETVZ1SUZBR0lLQ3RnRXE2WmMtUHUzZlJWTjdaZDl4ZU4waFdwbVFPTERVRElnMjdUZ2lONjBWeTlCdGx4VzhQZTFvcUdfaW1mUU1aTmtVOW1LQ0w5N1lWN2hCZ3I?oc=5", "source_name": "Market source", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOQk9UU2xCR0hBaktaT1FzOFU2S1JsWnZEUngtVV9oRzJyS0lQYXBoaDg1NEQ1b3NGNUhhU3UyZXNqMzFYb21VNGFnWVl1YV9VTExxQTVUQnJBRDdIZlZxZWpoMkhiTjRCR2RCSFpaaHdzOGZMdTFNNUljYXJWVm0xMm1iTGJ3UlNjTFJ6WmhOMHhmOENKMVJsczJCM3RSN0pUWFplVml1TUF1VV9VSzJmUDdzUHFwU1hQaG8zZEZkQ19OdEFYdDZYOWpUQ1NsZTVzdjBuM2lMWDFfUFZNeVZnRVl2c0RHUFoybUJOZDVaamdvQnc?oc=5", "source_name": "SynBioBeta", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) institutional owners may be pleased with recent gains after 29% loss over the past year", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-08T08:00:00+00:00", "published_display": "08 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Ginkgo Bioworks Holdings, Inc. (DNA) Dipped More Than Broader Market Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxNdXJVb0F6ZWt3dWxTRlhlMnl5MjN2M0NCWDY4SHBuQTlja0Y1N21LNnBtTVUzMm1SSnlHc0V1VVJBWGNXaTNFd0g5SHMxRDZ3WUpucnN6YVVGS2Y3WkFzSGN3YTFfRWJsX1FVWHpDS1NtZ3hxSjZpemxKMkJGUjRVMll0UGw?oc=5", "source_name": "Market source", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price Today: $8.29", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE9USzZmVUtTdzFEWHdib2szTDF3bFhhTXJqZk55cGFjbFktOGJGaWRWZmJKamJ2NkRYVHpHeTh4bFN3ekZONklFMkNIWlhOWUNTSlBWaGNn?oc=5", "source_name": "Gotrade", "published_at": "2026-01-09T20:48:22+00:00", "published_display": "09 Jan 2026 20:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Investors Shouldn't Be Surprised By Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 39% Share Price Plunge", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-17T08:00:00+00:00", "published_display": "17 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 107, "total_relevant": 65, "sentiment_summary": {"positive": 5, "negative": 10, "neutral": 50, "score": 48, "total": 65, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 18.5, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 12.31, "count": 24}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 7.91, "latest_week": "2026-07-17", "one_week_move": -13.0, "four_week_move": -13.7, "twelve_week_move": 0.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.833797, "market_dynamics_buy_signal": false, "relative_strength": -25.587143, "fair_value_gap": -66.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.2138, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-13.0% over one week, -13.7% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 18}, {"label": "Market source", "count": 10}, {"label": "simplywall.st", "count": 5}, {"label": "Sahm", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "PR Newswire", "count": 3}, {"label": "Stock Traders Daily", "count": 2}, {"label": "The Globe and Mail", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 24}, {"label": "Regulatory and legal", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-13.0% over one week, -13.7% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Ginkgo Bioworks (NYSE: DNA) CFO logs RSU vesting and tax sell-to-cover"}], "updated_at": "2026-07-22T02:49:00.735965+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}